Skip to main content
Year archive

Zealand Pharma — 2026 filings

All 16 regulatory filings released by Zealand Pharma (ZEAL) in 2026, sourced directly from the official regulator.

16 Filings
2026 Period
2026 filings (16)
Filing Released Lang
Zealand Pharma - Transactions related to share buy-back program (weeks 19-20, 2026)
Regulatory Filings
2026-05-14 Danish
Zealand Pharma - Transactions related to share buy-back program (weeks 19-20, 2026)
Transaction in Own Shares
2026-05-14 English
Zealand Pharma - Execution framework for share buy-back program
Regulatory Filings
2026-05-07 Danish
Zealand Pharma initiates USD 200 million / DKK 1.3 billion share buy-back program
Regulatory Filings
2026-05-07 Danish
Zealand Pharma and Roche to advance petrelintide, an amylin analog, to Phase 3 trials for chronic weight management
Regulatory Filings
2026-04-29 English
Zealand Pharma announces Boehringer Ingelheim's novel glucagon/GLP-1 dual agonist survodutide achieved significant weight loss of 16.6% delivering meaningful metabolic improvement in people with obesi
Regulatory Filings
2026-04-28 English
Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons
Director's Dealing
2026-04-22 English
Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons
Director's Dealing
2026-04-22 English
Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons
Director's Dealing
2026-04-19 English
Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons
Director's Dealing
2026-04-19 English
Total number of shares and voting rights in Zealand Pharma as of March 31, 2026
Share Issue/Capital Change
2026-03-31 English
Zealand Pharma increases its share capital as a result of the exercise of employee warrants
Share Issue/Capital Change
2026-03-19 English
Zealand Pharma announces positive Phase 2 results for petrelintide, an amylin analog with potential to redefine the weight management experience for people living with overweight and obesity
Regulatory Filings
2026-03-05 English
Zealand Pharma Announces Financial Results for the Full Year 2025
Annual Report (ESEF) FY 2025
2026-02-19 English
Zealand Pharma Announces Financial Results for the Full Year 2025
Annual Report FY 2025
2026-02-19 English
Zealand Pharma Announces Financial Results for the Full Year 2025
Earnings Release FY 2025
2026-02-19 English